Halozyme Therapeutics, Inc. Stock price

Equities

HALO

US40637H1095

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
40.68 USD -0.12% Intraday chart for Halozyme Therapeutics, Inc. +0.74% +10.06%
Sales 2024 * 957M Sales 2025 * 1.09B Capitalization 5.17B
Net income 2024 * 370M Net income 2025 * 484M EV / Sales 2024 * 6.67 x
Net Debt 2024 * 1.21B Net Debt 2025 * 426M EV / Sales 2025 * 5.14 x
P/E ratio 2024 *
13.5 x
P/E ratio 2025 *
9.86 x
Employees 373
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.93%
More Fundamentals * Assessed data
Dynamic Chart
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing MT
Transcript : Halozyme Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM
Transcript : Halozyme Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating MT
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance MT
Transcript : Halozyme Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021. CI
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83 MT
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M MT
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share MT
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares. CI
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 CI
Halozyme Therapeutics, Inc. authorizes a Buyback Plan. CI
More news
1 day-0.12%
1 week+0.74%
Current month+2.19%
1 month+2.11%
3 months+10.24%
6 months+5.80%
Current year+10.06%
More quotes
1 week
39.90
Extreme 39.9
41.03
1 month
39.39
Extreme 39.39
42.64
Current year
33.15
Extreme 33.15
42.64
1 year
29.85
Extreme 29.85
45.00
3 years
29.85
Extreme 29.85
59.46
5 years
12.71
Extreme 12.71
59.46
10 years
6.88
Extreme 6.88
59.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 14-01-05
Director of Finance/CFO 41 14-12-31
Compliance Officer 57 22-01-02
Members of the board TitleAgeSince
Director/Board Member 70 06-07-30
Chairman 59 15-08-04
Director/Board Member 59 23-02-02
More insiders
Date Price Change Volume
24-03-28 40.68 -0.12% 701,343
24-03-27 40.73 +1.62% 601,140
24-03-26 40.08 -0.84% 625,814
24-03-25 40.42 +0.85% 672,983
24-03-22 40.08 -0.35% 794,808

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
40.68 USD
Average target price
50.7 USD
Spread / Average Target
+24.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Halozyme Therapeutics, Inc. - Nasdaq